

FORM APPROVED OMB NO.: 0920-0840 EXPIRATION DATE:

MMP Provider Survey

Public reporting burden of this collection of information is estimated to average 30 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to: CDC, Project Clearance Officer, 1600 Clifton Road, MS D-24, Atlanta, GA 30333, ATTN: PRA (0920-0840). Do not send the completed form to this address.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Public Health Service Centers for Disease Control and Prevention Atlanta, GA 30333





MMP Provider Survey December 18, 2012 Page 1 of 16

1. Are you a physician (MD or DO), nurse practitioner, or physician assistant and you practice HIV medicine, i.e., order CD4 lymphocyte and HIV viral load tests for more than referral purposes or prescribe antiretroviral therapy? this survey, practicing HIV medicine may include the direct supervision of others who practice HIV medicine.
Yes
2. Are you a physician completing a fellowship, residency, or internship?
No
Yes 1 → We are only requesting responses from physicians who have completed their training, nurse practitioners, and physician assistants. Please stop here and return the survey using the self-addressed postage paid envelope. Thank you for your time.
A. BACKGROUND
3. How long have you been providing care for HIV-infected patients? years months
4. In what year did you complete medical school, nursing school, or physician assistant school?
5. What is your profession?
Physician 1
Nurse practitioner $2 \rightarrow \text{Skip to Q 8}$
Physician assistant
6. Are you board certified in any of the following? (Select all that apply.)
Internal Medicine
Family Practice
Pediatrics
Infectious Diseases
Obstetrics and Gynecology 5
Neurology 6
Dermatology 7
Surgery 8
Hematology-Oncology9
Immunology 10
Other board certification
7. In what year did you complete initial board certification?

Physicians skip to Q 9

<u>In</u>

ELIGIBILITY SCREENER

8. Are you certified by the HIV/AIDS Nursing Certification Board as an AIDS Certified Registered Nurse (ACRN) or an Advanced AIDS Certified Registered Nurse (AACRN)?

No 0
Yes 1
9. Are you a member of any of the following professional organizations? (Select all that apply.)
American Academy of HIV Medicine (AAHIVM)
HIV Medicine Association (HIVMA)
American Association of Nurses in AIDS Care (ANAC)
International Association of Physicians in AIDS Care (IAPAC) 4
10. Do you have American Academy of HIV Medicine (AAHIVM) specialist certification (AAHIVS)?
_
No
Yes 1
D. GUADA OTERIOTIOS OF VOUR PRACTICE
B. CHARACTERISTICS OF YOUR PRACTICE
For questions 11-21, please consider your work at <u>all</u> of your practice locations.
Patient care includes direct supervision of patient care.
11. How many hours per week do you devote to patient care in total including face-to-face contact, documentation, phone calls/emails to patients, educating families, reviewing tests, and consulting with other providers?
phone can stemans to patients, educating families, reviewing tests, and consulting with other providers:
12. What percentage of your patient care time do you devote to HIV-infected patients?
12. What percentage of your patient care time do you devote to mv-infected patients:
13. For how many HIV-infected individuals do you currently provide continuous and direct patient care?
14. In the past 3 years, have you provided continuous and direct medical care to a minimum of 25 patients with HIV?
No
Yes
15. Are you accepting new HIV-infected patients at this time?
No
Yes 1
16. Regarding the number of HIV patients you will be able to provide care for 5 years from now, which is most likely?
It will increase 1
It will stay the same2
It will decrease3
I will stop providing care for HIV patients 4
Unsure
17. Do you plan to leave clinical practice within the next 5 years?
No 0
Yes1
Unsure

MMP Provider Survey December 18, 2012 Page 3 of 16

you are a member of the National Health Service Corps or hold a J-1 or H1b visa)?
No 0
Yes1
19. Do you provide primary care for your HIV-infected patients (i.e., point of first contact, comprehensive care, and emphasis on prevention and coordination of care)?
No0
Yes1
20. Do you manage HIV treatment decisions involving antiretroviral drug resistance?
No 0
Yes1
21. Do you co-manage HIV patients? (Select one)
Note: Co-management refers to the practice of a more experienced HIV expert being available to oversee and consult with a less experienced HIV provider on the care of patients
Yes, I co-manage HIV patients and receive expert assistance \square ₁
Yes, I co-manage HIV patients and provide expert assistance
No, I do not co-manage patients
only at the practice where you received this survey. 22. How many minutes, on average, do you spend during the <u>initial visit</u> with an HIV-infected patient who is <u>entering</u> care for the <u>first time</u> ?
Minutes
NA, I do not see patients for initial visits (Skip to Q 24) 6
23. In your opinion, how often do you have sufficient time to provide all needed HIV related information to your HIV-infected patients who are entering care for the first time?
Always 1
Usually 2
Sometimes3
Never 4
24. How many minutes, on average, do you spend during a <u>follow-up visit</u> with an HIV-infected patient <u>after the initial</u> <u>evaluation is completed?</u>
Minutes
25. In your opinion, how often do you have sufficient time to provide all needed HIV-related information to your established HIV-infected patients?
Always 1

MMP Provider Survey December 18, 2012 Page 4 of 16

	Usually2 Sometimes					
vis nui	Does your practice utilize an <u>integrated team</u> who it by providing pre-visit, post-visit, or between-vis ses, social workers, case managers, mental healt unselors.	it contact wit	h HIV-infected	patients? Th	nese teams m	ay include
	No0 Yes1					
	Don't know 8					
27.	Please indicate your level of satisfaction with the	following are	as of your HI	/ medical pra	actice:	
		Very satisfied	Satisfied	Neutral	Un- satisfied	Very un- satisfied
a.	Salary or reimbursement rates	□ 1	2	□3	□ 4	□ 5
b.	Amount of time required and available for documentation and other administrative work	□1	□ 2	□ 3	□ 4	□ 5
C.	Work schedule and/or on call responsibilities	□1	□ 2	□ 3	□ 4	□ 5
d.	Availability of supportive services to assist with patient management	□1	□ 2	□ 3	□ 4	□ 5
e.	Support and coverage from other HIV providers	□1	□ 2	□ 3	□ 4	□ 5
f.	Availability of specialists for consultation and referral	□1	□ 2	□ 3	□ 4	□ 5
g.	Amount of effort required to keep up with clinical and/or pharmaceutical advances	□1	□ 2	□ 3	□ 4	□ 5
c.	CHARACTERISTICS OF YOUR HIV-INFECTED PA	TIENTS				
	f you provide HIV care at more than one practice, where you received this survey.	in this section	n consider the	patients at t	he practice	
	Approximately what proportion of your HIV-infectual 100%.	ted patients fa	all into the foll	owing catego	ories? The to	tal should
	a. American Indian or Alaska Native	%				
	b. Asian	%				
	c. Black or African American	%				
	d. Hispanic or Latino	%				
	e. Native Hawaiian or Other Pacific Islander	%				
	f M/bito	0/				

MMP Provider Survey December 18, 2012 Page 5 of 16

equa	approximately what proportion of your HIV-in	fected patie	nts fall into	the following	categorie	s? The total	should
	d 100%.						
	a. Age12 years and under	%					
	b. Age 13-24 years	%					
	c. Age 25-64 years	%					
	d. Age 65 years and over	%					
	Total 1 0	0 %					
). A	approximately what percentage of your HIV-ii	nfected patie	nts fall into	the following	ı categori	es? The total	can
	il more than 100%.	· 		- 			
ć	a. Women	L		%			
ŀ	b. Men who have sex with men	Γ		%			
(c. Men who have sex with women	Γ		%			
(d. Transgender (male to female or female to	L male) _[l I [%]			
	e. Injecting drug users	Ĺ	44	 %			
		L		,,			
. V	When your patients miss their scheduled folk	ow-un visits.	how often i	is it due to the	e following	n reasons?	
	, ,	Never	Rarely	Sometimes	Often	Very often	Don't
							know
\exists							
	Incarceration or legal detention	□1	□ 2	□3	□ 4	□ 5	□ 8
						1	
	Homelessness	□1	□ 2	□ 3	□ 4	□ 5	□ 8
	Homelessness Emotional or psychological barriers related to HIV (e.g., stigma, denial, fear, anger)	□ 1 □ 1	□ 2 □ 2	□ 3 □ 3	□ 4 □ 4	□ 5 □ 5	
	Emotional or psychological barriers related to						□ 8
	Emotional or psychological barriers related to HIV (e.g., stigma, denial, fear, anger)		□ 2	□3	□ 4	□ 5	□ 8 □ 8
	Emotional or psychological barriers related to HIV (e.g., stigma, denial, fear, anger) Mental health problems	1 	□ 2 □ 2	3 3	□ 4 □ 4	5 5	

MMP Provider Survey December 18, 2012 Page 6 of 16

	Child care problems		□ 2	□3	□ 4	□ 5	8
	Reluctance to admit not following provider's advice (e.g., regarding ART use or risk reduction measures)	□1	□ 2	□3	□ 4	□ 5	□8
2. Do	you agree with the following statements abo	out services	s provided t	o patients a	your pract	ice?	
			Yes	No	Don't know		
	Practice routinely contacts patients prior to their mail, phone, or other)	appointmen	ts as a remin	der (via	□1	□2	□8
	Practice routinely follows-up on patients who mis phone, or other)	ss their appo	ointments (via	a mail,	□1	□2	□8
	Practice provides patient navigation services (e.ças needed)	g., accompa	nying to app	ointments	□1	□2	□8
	You or your practice routinely reinforces the valu	ıe of follow-ι	ıp visits		□1	□ 2	□8
	Practice has a program to systematically moniton (e.g., monitoring visit adherence, gaps in care, o				□1	□ 2	□8
	Practice offers care to persons with any income	level and in	surance stat	us	□1	□ 2	□ 8
). P <i>F</i>	ATIENT MANAGEMENT						
f you he p	provide HIV care at more than one practice, ractice where you received this survey. mong patients for whom there are no barriers						prescribe
If you the p	ı provide HIV care at more than one practice, ractice where you received this survey.						prescribe
f you the p	provide HIV care at more than one practice, ractice where you received this survey. mong patients for whom there are no barriers	or contrain					prescribe
f you he p	provide HIV care at more than one practice, ractice where you received this survey. mong patients for whom there are no barriers (Select one.)	or contrain					prescribe
f you the p	provide HIV care at more than one practice, ractice where you received this survey. mong patients for whom there are no barriers (Select one.) CD4 count <200 cells/mm³	s or contrain 1 2					prescribe
f you he p	n provide HIV care at more than one practice, ractice where you received this survey. mong patients for whom there are no barriers (Select one.) CD4 count <200 cells/mm³	s or contrain 1 2 3					prescribe
f you the p	n provide HIV care at more than one practice, ractice where you received this survey. mong patients for whom there are no barriers (Select one.) CD4 count <200 cells/mm³	s or contrain 1 2 3 4					prescribe
If you the p	mong patients for whom there are no barriers (Select one.) CD4 count <200 cells/mm³ CD4 count <350 cells/mm³ CD4 count <500 cells/mm³ Treat regardless of CD4 count N/A, I do not prescribe ART (Skip to Q 36)	s or contrain 1 2 3 4 6	ndications to	o treatment,	when woul	d you first p	prescribe
f you the p	mong patients for whom there are no barriers (Select one.) CD4 count <200 cells/mm³ CD4 count <500 cells/mm³ Treat regardless of CD4 count N/A, I do not prescribe ART (Skip to Q 36) or what percentage of your patients do you cu	s or contrain 1 2 3 4 6	ndications to	o treatment,	when woul	d you first p	prescribe
If you the p	mong patients for whom there are no barriers (Select one.) CD4 count <200 cells/mm³ CD4 count <500 cells/mm³ Treat regardless of CD4 count N/A, I do not prescribe ART (Skip to Q 36) or what percentage of your patients do you cut ow	s or contrain 1 2 3 4 6	ndications to	o treatment,	when woul	d you first p	prescribe
If you the p	provide HIV care at more than one practice, ractice where you received this survey. mong patients for whom there are no barriers (Select one.) CD4 count <200 cells/mm³ CD4 count <350 cells/mm³ CD4 count <500 cells/mm³ Treat regardless of CD4 count N/A, I do not prescribe ART (Skip to Q 36) or what percentage of your patients do you cut o%	s or contrain 1 2 3 4 6	ndications to	o treatment,	when woul	d you first p	prescribe
If you the p	mong patients for whom there are no barriers (Select one.) CD4 count <200 cells/mm³ CD4 count <500 cells/mm³ Treat regardless of CD4 count N/A, I do not prescribe ART (Skip to Q 36) or what percentage of your patients do you cut ow	s or contrain 1 2 3 4 6	ndications to	o treatment,	when woul	d you first p	prescribe

MMP Provider Survey December 18, 2012 Page 7 of 16

		0	1-25%	26-50%	51-75%	75-100%
a.	Patient refusal or unwillingness to commit to treatment	□1	□ 2	□ 3	□ 4	□5
b.	Patient has medical problem that may make long-term adherence difficult (e.g., substance abuse, mental health, or other illness)	□1	□ 2	□3	□ 4	□5
C.	Patient has social issue that may make long-term adherence difficult (e.g., homeless, incarcerated, migrant)	□1	□ 2	□3	□ 4	□5
d.	Inability to construct an effective regimen with acceptable side effects	□1	□ 2	□3	□ 4	□5
e.	Inability to pay for medications or medication coverage delays	□1	□ 2	□3	□ 4	□5
f.	You do not agree with current guidelines to treat HIV-infected patients at all CD4 levels	□1	□ 2	□3	□ 4	□5

36. Please indicate the extent to which you agree with the following statement: the availability of medication provided by the following prescription drug plans is sufficient to meet my patients' HIV treatment needs:

		Strongly agree	Somewhat agree	Neither agree nor disagree	Somewhat disagree	Strongly disagree	N/A I have no patients in this plan	Don't know
a.	ADAP (AIDS Drug Assistance Program)	□1	□ 2	□ 3	□ 4	□ 5	□ 6	□8
b.	Medicare prescription drug plan	□1	□ 2	□ 3	□ 4	□ 5	□ 6	□8
C.	Medicaid	□1	□ 2	□ 3	□ 4	□ 5	□ 6	□ 8
d.	Commercial insurance	□1	□ 2	□3	□ 4	□ 5	□ 6	□8
e.	Pharmaceutical industry drug assistance plans	□1	□ 2	□ 3	□ 4	□ 5	□ 6	□8

37. For what proportion of your patients who are new to HIV care do you order an HIV genotype as part of their initial evaluation?

All patients
More than half2
About half
Less than half
Few or none
N/A I do not perform initial evaluations on HIV-infected natients

Questions 38-44 refer to assessments and interventions, such as counseling, education, and referrals, that you may perform as part of your HIV practice.

38. For what proportion of the HIV-infected patients you see for continuous or repeated care do you perform the following?

		Most or all	More than half	About half	Less than half	Few or none	N/A I don't prescribe ART
	ANTIRETROVIRAL TREATMENT	_	_	_	-	_	_
a.	For patients who choose to postpone the start of treatment, periodically re-offer them ART	□1	□ 2	□ 3	□ 4	□ 5	□ 6
b.	For patients not yet started on ART, discuss the benefit of ART in reducing risk of transmitting HIV to others	□1	□ 2	□3	□ 4	□ 5	
C.	For patients using ART, assess treatment adherence at every visit	□1	□ 2	□3	□ 4	□ 5	
d.	Offer education and advice about tools to increase adherence for patients on ART (e.g., dose-reminder alarms, diaries, and pill boxes)	□1	□ 2	□3	□ 4	□ 5	
e.	For patients who are non-adherent to ART, refer for supportive services as needed	□1	□ 2	□3	□ 4	□5	

39. For what proportion of the HIV-infected patients you see for continuous or repeated care do you perform the following?

IUIIUI	wing?						
		Most or all	More than half	About half	Less than half	Few or none	N/A I don't see patients for initial visits
	SEXUAL RISK REDUCTION						
a.	Ask about any new sexual partners and number and gender of partners and assess ongoing risk behaviors every 6 months	□1	□ 2	□3	□ 4	□ 5	
b.	Ask about symptoms of STDs since the last visit in sexually active patients	□1	□ 2	□3	□ 4	□ 5	
C.	Provide safer sex counseling at each visit for patients with ongoing risky sexual behaviors or detectable viral load	□1	□ 2	□3	□ 4	□ 5	
d.	Offer condoms to sexually active patients	□1	□ 2	□3	□ 4	□ 5	
e.	Ask patients during their initial evaluation if all sexual partners since time of diagnosis have been notified of possible HIV exposure	□1	□ 2	□3	□ 4	□ 5	□ 6
f.	Ask patients during their follow-up visits if any new sexual partners have been notified of possible HIV exposure since their last visit	□1	□ 2	□3	□ 4	□ 5	

MMP Provider Survey December 18, 2012 Page 9 of 16

g.	Ask patients with newly diagnosed syphilis, gonorrhea, chlamydia, trichomoniasis (in women only) and HSV-2 if all sex partners have been informed of possible HIV exposure	□1	□ 2	□3	□ 4	□ 5	
h.	Encourage patients to disclose their HIV status to all sex partners since the time of their diagnosis	□1	□ 2	□3	□ 4	□5	
i.	Refer patients to health department to discuss sex partners who have not been informed of their exposure and to arrange for their notification and referral for HIV testing.	<u>□ 1</u>	<u>□ 2</u>	□ 3	□ 4	<u> </u>	

40. For what proportion of the HIV-infected patients you see for continuous or repeated care do you perform the following?

fol	lov	vin	g?	

10110	vinia:							
		Most or all	More than half	About half	Less than half	Few or none	N/A I have no patients who inject drugs	N/A I don't see patients for initial visits
	ALCOHOL AND DRUG USE RISK REDUCTION							
a.	Assess use of alcohol, recreational drugs, illicit drugs, and elicit injected drugs every 6 months	□1	□ 2	□3	□ 4	□ 5		
b.	Ask injection drug users during their initial evaluation if all injection partners have been informed of possible HIV exposure		□ 2	□3	□ 4	□ 5	□ 6	□ 7
C.	Ask injection drug users at follow-up visits if any new injection partners have been informed of possible HIV exposure since their last visit		□ 2	□3	□ 4	□ 5	□ 6	
d.	Encourage patients to disclose their HIV status to all injection partners since the time of their HIV diagnosis		□ 2	□3	□ 4	□ 5	□ 6	
e.	Refer patients to health department to discuss drug injection partners who have not been informed of their exposure and to arrange for their notification and referral for HIV testing.	□ 1	□2	□3	□ 4	□5	□ 6	
f.	For patients who abuse alcohol or drugs, make referrals for appropriate specialty services	□1	□ 2	□3	□ 4	□ 5	□ 6	
g.	Inform patients who share drug injection equipment about sources of sterile syringes (e.g., pharmacies, syringe programs, legal prescription in some states)	□1	□ 2	□3	□ 4	□ 5	□ 6	

41. Do you provide	care for HIV-infected female patients?
No	\square 0 → Please skip to Q 43.
Yes	1

42. For what proportion of the HIV-infected women you see for continuous or repeated care do you perform the following?

Most or all	More than half	About half	Less than half	Few or none
-------------	----------------	------------	----------------	-------------

	REPRODUCTIVE HEALTH, FEMALE PATIENTS WITH HIV					
a.	Assess the reproductive plans of patients aged 12-45 years	□ 1	□ 2	□3	□ 4	□5
b.	Inform patients about the risk of perinatal transmission should they become pregnant	□ 1	□ 2	□3	□ 4	□5
C.	For patients who wish to avoid pregnancy, provide or prescribe effective contraception or refer to another provider for contraception needs	□1	□ 2	□3	□ 4	□5
d.	Advise patients using medical or surgical contraception to also use condoms to prevent HIV transmission	□ 1	□ 2	□3	□ 4	□ 5
e.	Refer patients who wish to conceive to clinicians skilled in preconception counseling of HIV-infected women	□1	□ 2	□3	□ 4	□ 5
f.	Inform patients that using ART can prevent perinatal transmission should they become pregnant	□ 1	□ 2	□3	□ 4	□ 5

43. Do you provide care for HIV-infected male patients with female partners?

44. For what proportion of the HIV-infected patients you see for continuous or repeated care, who are men with female partners, do you perform the following?

		Most or all	More than half	About half	Less than half	Few or none
	REPRODUCTIVE HEALTH, MALE PATIENTS					
a.	Inform patients who have female partners about the risk of perinatal transmission should their partner become pregnant	□1	□ 2	□3	□ 4	□ 5
b.	Assess patients' reproductive plans and refer patients who wish to conceive with a female partner to clinicians skilled in preconception counseling of HIV-infected persons	□1	□ 2	□3	□ 4	□ 5
C.	For patients who wish to avoid conceiving a child, provide information about vasectomy or refer to another provider to do this	□1	□ 2	□3	□ 4	□ 5
d.	Advise patients who are sterile or using another form of contraception to also use condoms to prevent HIV transmission	□1	□ 2	□3	□ 4	□ 5

E. ANTIRETROVIRAL PROPHYLAXIS FOR HIV-NEGATIVE PATIENTS

	prophylaxis (PrEP) of HIV infection?
	No 0 → Skip to question 47
	Yes1
	46. For whom have you prescribed continuous daily dosing of tenofovir/emtricitabine (Truvada®) for PrEP? (Select al that apply)
	Men who have sex with men
	Men who have sex with women
	Women who have sex with men
	Uninfected partners in serodiscordant couples attempting to conceive \square_4
	Injecting drug users
	Other group, specify:
	47. Have you ever prescribed antiretroviral medication for non-occupational post-exposure prophylaxis (nPEP)?
	No 0 → Skip to question 49
	Yes1
	48. For whom have you prescribed antiretroviral medication for nPEP? (Select all that apply)
	Men who have sex with men
	Men who have sex with women
	Women who have sex with men
	Uninfected partners in serodiscordant couples attempting to conceive4
	Injecting drug users□₅
	Other group, specify:6
	F. SOURCES OF INFORMATION AND CONTINUING EDUCATION / CONTINUING MEDICAL EDUCATION
	49. Which sources of information on HIV care and treatment have you used in the past year? (Select all that apply.)
	Published Guidelines / Recommendations
	Infectious Disease Society of America (IDSA) / HIVMA Primary Care Guidelines $\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ $
	Department of Health and Human Services (DHHS) Antiretroviral Treatment Guidelines $\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ $
	International Antiviral Society – USA (IAS-USA) Antiretroviral Treatment of Adult HIV Infection Recommendations
	CDC / IDSA / HIVMA / National Institutes of Health (NIH) Guidelines for the Prevention of Opportunistic Infections in -Adults and Adolescents
	CDC / IDSA / HIVMA / Health Resources and Services Administration (HRSA) Incorporating HIV Prevention into the Medical Care of Persons Living with HIV (Published July 2003 MMWR)
	CDC Interim Guidance: Pre-exposure Prophylaxis for Men who have Sex with Men (Published January 2011 MMWR)
	CDC Interim Guidance: Pre-exposure Prophylaxis for Heterosexually Active Adults (Published August 2012 MMWR)
	CDC Guidelines for Non-occupational Post-exposure (nPEP) Prophylaxis Adults (Published January 2005 MMWR)

Other Resources
International/national conferences
National/Regional AIDS Education & Training Centers (AETC)
Continuing Medical Education / Continuing education courses
Colleagues
Medical journals/textbooks
Websites with clinical information (e.g., IAS-USA, HIV InSite, Clinical Care Options) \square 14
Pharmaceutical representatives/pharmaceutical sponsored meetings
Medical associations
National HIV Telephone Consultation Service (Warmline)
CDC Prevention is Care materials (http://www.cdc.gov/actagainstaids/pic/)
Other, specify:
50. How many HIV-specific Category 1 continuing medical education/continuing education (CME/CE) credits have you earned in the past 12 months?
5-92
10 or more 3
51. In the past 3 years have you earned at least 10 hours per year of Category 1 CME/CE credits each year addressing the diagnosis, treatment, or epidemiology of HIV disease?
No 0
Yes1
52. In the past 3 years have you earned at least 40 hours of Category 1 CME/CE credits addressing the diagnosis, treatment, or epidemiology of HIV disease?
No 0
Yes
G. OPINION ON POSSIBLE CHANGES TO THE MEDICAL MONITORING PROJECT (MMP)
The Medical Monitoring Project (MMP) is considering changing the way HIV-infected individuals are selected for participation in order to include persons not in care as well as those receiving care. If adopted, individuals would be sampled from health department lists of HIV-infected persons and would be recruited directly by local health department staff. Providers would still be asked to help locate patients and to grant access to participants' medical records.
53. If the proposed change to MMP described above were adopted, how would your interest in participating with MMP be affected?
Interest would be decreased 1
Interest would be unaffected2
Interest would be increased
Not sure 4
H. PROVIDER CHARACTERISTICS 54. What is your age in years?
34. WHALIS YOU AYE III YEAIS! LEELE

55. What is your gender?
Male 1
Female2
Transgender 3
56. Do you consider yourself to be:
Heterosexual or straight 1
Gay or lesbian2
Bisexual3
57. Do you consider yourself to be Hispanic or Latino/a?
No $0 \rightarrow$ Skip to question 59
Yes1
58. Which best describes your Hispanic ancestry? (Select all that apply.)
Mexican, Mexican American, Chicano/a 1
Puerto Rican2
Cuban3
Another Hispanic, Latino/a, Spanish origin ₄ → Please specify:
59. Which racial group or groups do you consider yourself to be in? (Select all that apply.)
American Indian or Alaska Native1
Asian2
Black or African-American
Native Hawaiian or other Pacific Islander 4
White 5
60. Do you communicate in another language besides English to provide medical care (i.e. without the use of an interpreter)?
No $0 \rightarrow$ Please stop here. Thank you for your time.
Yes1
C4. If you is substantially we have a substantial and its larger
61. If yes, in what other language/s do you provide medical care?
Spanish 1
Other2 → Please specify:

Thank you for your participation!



For more information on MMP, please go to: http://www.cdc.gov/hiv/topics/treatment/MMP/index.htm